Literature DB >> 8697162

Post-stent management with a pneumatic groin compression device and self injected low molecular weight heparin.

R H Stables1, U Sigwart.   

Abstract

BACKGROUND: The benefits of intracoronary stent implantation are offset by an increased risk of complications at the arterial puncture site and a prolonged hospital stay. Much of this morbidity can be attributed to the generally perceived need to achieve systemic anticoagulation after stent implantation. AIM: To test a simplified protocol for post-stent management using the Femostop pneumatic groin compression device and low molecular weight (fractionated) heparin (LMWH) administered by subcutaneous injection. PATIENTS: A case series of 100 consecutive patients, with stable angina pectoris, undergoing coronary stenting for a suboptimal result after conventional balloon angioplasty.
METHODS: All patients were managed with a new post-stent protocol using the Femostop pneumatic groin compression device and LMWH. The incidence of complications and the length of hospital stay were recorded.
RESULTS: The clinical course was uncomplicated in 92 patients and their discharge from hospital was achieved on the first post-procedural day for 44 patients and on the second for the remaining 48. The rate of vascular or bleeding complications was 6%.
CONCLUSIONS: LMWH administered by subcutaneous injection may provide a practical and effective alternative to the use of intravenous heparin when systemic anticoagulation is used after stent implantation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8697162      PMCID: PMC484382          DOI: 10.1136/hrt.75.6.588

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  9 in total

Review 1.  Low molecular weight heparin treatment of venous thromboembolism.

Authors:  R D Hull; G F Pineo
Journal:  Prog Cardiovasc Dis       Date:  1994 Sep-Oct       Impact factor: 8.194

Review 2.  Prophylaxis of postoperative thromboembolism with low molecular weight heparins.

Authors:  L N Jørgensen; P Wille-Jørgensen; O Hauch
Journal:  Br J Surg       Date:  1993-06       Impact factor: 6.939

Review 3.  Low-molecular-weight heparin.

Authors:  H Wolf
Journal:  Med Clin North Am       Date:  1994-05       Impact factor: 5.456

4.  A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group.

Authors:  P W Serruys; P de Jaegere; F Kiemeneij; C Macaya; W Rutsch; G Heyndrickx; H Emanuelsson; J Marco; V Legrand; P Materne
Journal:  N Engl J Med       Date:  1994-08-25       Impact factor: 91.245

5.  Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.

Authors:  T E Warkentin; M N Levine; J Hirsh; P Horsewood; R S Roberts; M Gent; J G Kelton
Journal:  N Engl J Med       Date:  1995-05-18       Impact factor: 91.245

6.  A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators.

Authors:  D L Fischman; M B Leon; D S Baim; R A Schatz; M P Savage; I Penn; K Detre; L Veltri; D Ricci; M Nobuyoshi
Journal:  N Engl J Med       Date:  1994-08-25       Impact factor: 91.245

Review 7.  Rationale for development of low-molecular-weight heparins and their clinical potential in the prevention of postoperative venous thrombosis.

Authors:  J Hirsh
Journal:  Am J Surg       Date:  1991-04       Impact factor: 2.565

Review 8.  Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs).

Authors:  M M Samama; L Bara; G T Gerotziafas
Journal:  Haemostasis       Date:  1994 Mar-Apr

Review 9.  Low-molecular-weight heparins for the treatment of deep-vein thrombosis.

Authors:  M J Cziraky; S A Spinler
Journal:  Clin Pharm       Date:  1993-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.